Showing 2931 results for "hemophilia A"

Filter By

Sangamo to regain rights to hemophilia A gene therapy

Sangamo Therapeutics will regain full rights to develop and market giroctocogene fitelparvovec, a gene therapy candidate for adults with moderately severe to severe hemophilia A, after Pfizer decided to end its involvement in the program. Pfizer’s decision not to advance into regulatory submissions came despite positive…

FDA approves Alhemo for hemophilia A or B with inhibitors

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s concizumab, which will be sold under the brand name Alhemo, as a daily treatment to prevent or reduce the frequency of bleeding episodes in certain adults and adolescents with hemophilia. Eligible patients are those with hemophilia…

Altuviiio bests others as hemophilia A factor replacement therapy

For adults and adolescents with hemophilia A without inhibitors, Altuviiio (efanesoctocog alfa) may work better than other standard or extended half-life factor replacement therapies at preventing bleeding episodes, while requiring less frequent injections, a study found. Researchers made an indirect comparison of data from XTEND-1 (NCT04161495) and published…

What do people with hemophilia actually need?

When someone we love is diagnosed with a chronic illness, our instincts often compel us to search for solutions: stricter routines, healthier diets, more discipline, or the willpower to push through. While self-help culture tends to praise these strategies, our family’s experience with chronic illness has shown that they can…

Liver cancer seen as common risk for men with hemophilia and HIV

Men with hemophilia and infected with the human immunodeficiency virus (HIV) are at a high risk of developing certain types of cancer that are more likely in people with HIV, according to a recent study in Japan. These cancers, called non-acquired immunodeficiency syndrome-defining malignancies or NADMs, included liver cancer,…